KalVista Pharmaceuticals, Inc. $KALV Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC cut its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 54.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,828 shares of the specialty pharmaceutical company’s stock after selling 26,202 shares during the period. SG Americas Securities LLC’s holdings in KalVista Pharmaceuticals were worth $439,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in KALV. BNP Paribas Financial Markets boosted its stake in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $55,000. Truvestments Capital LLC lifted its holdings in KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 3,360 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in KalVista Pharmaceuticals by 816.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock worth $91,000 after buying an additional 7,180 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in KalVista Pharmaceuticals in the 3rd quarter valued at approximately $145,000.

Insider Activity

In other news, CFO Brian Piekos sold 1,489 shares of KalVista Pharmaceuticals stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $39,875.42. Following the completion of the sale, the chief financial officer directly owned 21,661 shares of the company’s stock, valued at approximately $580,081.58. The trade was a 6.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Paul K. Audhya sold 2,239 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total transaction of $59,960.42. Following the transaction, the insider owned 150,260 shares of the company’s stock, valued at approximately $4,023,962.80. The trade was a 1.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,971 shares of company stock valued at $965,493 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on KALV. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 21st. JonesTrading cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. Leerink Partners lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Wall Street Zen raised KalVista Pharmaceuticals to a “hold” rating in a research note on Saturday, June 13th. Finally, HC Wainwright downgraded KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $37.00 to $27.00 in a report on Friday, May 1st. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $33.25.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $27.00 on Thursday. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.83 and a fifty-two week high of $27.00. The firm’s 50 day moving average price is $26.74 and its 200 day moving average price is $20.30. The company has a quick ratio of 5.10, a current ratio of 5.17 and a debt-to-equity ratio of 8.18. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -7.80 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. As a group, equities research analysts predict that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.